Unknown

Dataset Information

0

Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4.


ABSTRACT:

Background

Oral supplementation of anserine/carnosine helps preserve cognitive functions in healthy older adults. Mild cognitive impairment (MCI) is a transition between cognitive-normal and dementia. Therefore, it needs to investigate whether anserine/carnosine supplementation (ACS) has effects on subjects with MCI.

Methods

A randomized, double-blind, placebo-controlled 12-week trial was performed. Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1). Evaluation of cognitive change was conducted utilizing a psychometric test battery.

Results

The score improvement in the global Clinical Dementia Rating (gloCDR) was superior in the active group than placebo (p = 0.023). No beneficial effect in the active group was detected in the other psychometric tests including the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale, and the Alzheimer's Disease Assessment Scale (ADAS). When APOE4 positive (APOE4 (+)) or negative (APOE4 (-)) subjects were separately analyzed, beneficial change in the APOE4 (+) subjects was observed in MMSE (p = 0.025) as well as in gloCDR (p = 0.026).

Conclusions

The present study might suggest that protective effects against cognitive decline in APOE4 (+) MCI subjects exist.

SUBMITTER: Masuoka N 

PROVIDER: S-EPMC6683059 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4.

Masuoka Nobutaka N   Yoshimine Chitose C   Hori Marie M   Tanaka Mieko M   Asada Takashi T   Abe Keiichi K   Hisatsune Tatsuhiro T  

Nutrients 20190717 7


<h4>Background</h4>Oral supplementation of anserine/carnosine helps preserve cognitive functions in healthy older adults. Mild cognitive impairment (MCI) is a transition between cognitive-normal and dementia. Therefore, it needs to investigate whether anserine/carnosine supplementation (ACS) has effects on subjects with MCI.<h4>Methods</h4>A randomized, double-blind, placebo-controlled 12-week trial was performed. Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg o  ...[more]

Similar Datasets

| S-EPMC7998783 | biostudies-literature
| S-EPMC4927867 | biostudies-other
| S-EPMC9116398 | biostudies-literature
| S-EPMC6093614 | biostudies-literature
2015-08-05 | E-GEOD-63063 | biostudies-arrayexpress
| S-EPMC8004088 | biostudies-literature
| S-EPMC5303668 | biostudies-literature
2024-09-26 | PXD056265 |
| S-EPMC4397072 | biostudies-literature
2015-08-05 | E-GEOD-63061 | biostudies-arrayexpress